Interestingly, native bacterial-derived EVs combined with anti-PD-1 [154], as well as bacterial-derived EVs engineered to express PD-1 [153], both improved tumor-infiltrating CD8+ T cell responses. The gene discussed is CD8A; the disease is neoplasm.